Short-Course External Beam Radiotherapy Versus Brachytherapy for Palliation of Dysphagia in Esophageal Cancer: A Matched Comparison of Two Prospective Trials

Short-course external beam radiotherapy (EBRT) and intraluminal brachytherapy are both accepted treatments for the palliation of dysphagia in patients with incurable esophageal cancer. We compared the effects of both treatments from two prospective studies. We performed a multicenter prospective coh...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2020-08, Vol.15 (8), p.1361-1368
Main Authors: Jeene, Paul M., Vermeulen, Bram D., Rozema, Tom, Braam, Pètra M., Lips, Irene, Muller, Karin, van Kampen, Daphne, Homs, Marjolein Y.V., Oppedijk, Vera, Berbée, Maaike, van Rossum, Peter S.N., el Sharouni, Sherif, Siersema, Peter D., Hulshof, Maarten C.C.M.
Format: Article
Language:English
Subjects:
Brachytherapy
Deglutition Disorders - etiology
Deglutition Disorders - radiotherapy
Dysphagia
Esophageal cancer
Esophageal Neoplasms - complications
Esophageal Neoplasms - radiotherapy
External beam radiotherapy
Humans
Lung Neoplasms
Palliation
Prospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Short-course external beam radiotherapy (EBRT) and intraluminal brachytherapy are both accepted treatments for the palliation of dysphagia in patients with incurable esophageal cancer. We compared the effects of both treatments from two prospective studies. We performed a multicenter prospective cohort study of patients with metastasized or otherwise incurable esophageal cancer requiring palliation of dysphagia from September 2016 to March 2019. Patients were treated with EBRT in five fractions of 4 Gy. Data were compared with all patients treated with a single brachytherapy dose of 12 Gy in the SIREC (Stent or Intraluminal Radiotherapy for inoperable Esophageal Cancer) trial, both between the original cohorts and between 1:1 propensity score–matched cohorts. The primary end point was an improvement of dysphagia at 3 months without reintervention. The secondary end points included toxicity and time-to-effect. A total of 115 patients treated with EBRT and 93 patients who underwent brachytherapy were eligible for analysis. In the original cohorts, dysphagia improved after EBRT in 79% of patients compared with 64% after brachytherapy (p = 0.058). Propensity score matching resulted in 69 patients in each cohort well-balanced at baseline. Improvement of dysphagia was observed in 83% after EBRT versus 64% after brachytherapy (p = 0.048). In responding patients, improvement of dysphagia at 2 weeks was observed in 67% after EBRT compared with 35% after brachytherapy, and the maximum effect was reached after 4 weeks in 55% and 33%, respectively. Severe toxicity occurred in 3% of patients after EBRT compared with 13% after brachytherapy. Short-course EBRT appears at least as effective as brachytherapy in the palliation of dysphagia in patients with esophageal cancer.
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2020.04.032